New Key Statistics Module, Z-Score and F-Score
OTCPK:CMOPF Key Ratios
| Market Cap $ M | 1,284.21 |
| Enterprise Value $ M | 1,232.19 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 10.50 |
| Price/Book | 2.91 |
| Price/Sales | 13.06 |
| Price/Free Cash Flow | 66.21 |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 100.00 |
| EPS (TTM) $ | -0.33 |
| Beneish M-Score | -2.89 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -50.10 |
| EV-to-EBIT | 113.88 |
| EV-to-EBITDA | 47.41 |
| PEG | -- |
| Shares Outstanding M | 16.05 |
| Net Margin (%) | -5.18 |
| Operating Margin % | 7.86 |
| Pre-tax Margin (%) | 1.76 |
| Quick Ratio | 3.42 |
| Current Ratio | 3.98 |
| ROA % (ttm) | -0.69 |
| ROE % (ttm) | -1.09 |
| ROIC % (ttm) | -3.46 |
| Dividend Yield % | 2.70 |
| Altman Z-Score | 6.87 |
CMOPF Number of Guru Trades
CMOPF Volume of Guru Trades
Gurus Latest Trades with OTCPK:CMOPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OTCPK:CMOPF is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Cosmo Pharmaceuticals NV Insider Transactions
No Available Data
News about OTCPK:CMOPF
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers